207 related articles for article (PubMed ID: 36094848)
21. Cytogenetic abnormalities in systemic mastocytosis: WHO subcategory-specific incidence and prognostic impact among 348 informative cases.
Shah S; Pardanani A; Elala YC; Lasho TL; Patnaik MM; Reichard KK; Hanson CA; Ketterling RP; Tefferi A
Am J Hematol; 2018 Dec; 93(12):1461-1466. PubMed ID: 30152525
[TBL] [Abstract][Full Text] [Related]
22. Systemic mastocytosis in adults: 2019 update on diagnosis, risk stratification and management.
Pardanani A
Am J Hematol; 2019 Mar; 94(3):363-377. PubMed ID: 30536695
[TBL] [Abstract][Full Text] [Related]
23. Granularity in disease classification impacts survival prediction in advanced systemic mastocytosis: A single institution study of 329 informative cases.
Tefferi A; Abdelmagid M; Al-Kali A; Patnaik M; Hogan WJ; Begna K; Gangat N; Orazi A; Chen D; Reichard KK; Pardanani A
Am J Hematol; 2024 Jan; 99(1):21-27. PubMed ID: 37772442
[TBL] [Abstract][Full Text] [Related]
24. Mast cell leukemia.
Georgin-Lavialle S; Lhermitte L; Dubreuil P; Chandesris MO; Hermine O; Damaj G
Blood; 2013 Feb; 121(8):1285-95. PubMed ID: 23243287
[TBL] [Abstract][Full Text] [Related]
25. Cytogenetic and molecular aberrations and worse outcome for male patients in systemic mastocytosis.
Kluin-Nelemans HC; Jawhar M; Reiter A; van Anrooij B; Gotlib J; Hartmann K; Illerhaus A; Oude Elberink HNG; Gorska A; Niedoszytko M; Lange M; Scaffidi L; Zanotti R; Bonadonna P; Perkins C; Elena C; Malcovati L; Shoumariyeh K; von Bubnoff N; Müller S; Triggiani M; Parente R; Schwaab J; Kundi M; Fortina AB; Caroppo F; Brockow K; Zink A; Fuchs D; Angelova-Fischer I; Yavuz AS; Doubek M; Mattsson M; Hagglund H; Panse J; Simonowski A; Sabato V; Schug T; Jentzsch M; Breynaert C; Várkonyi J; Kennedy V; Hermine O; Rossignol J; Arock M; Valent P; Sperr WR
Theranostics; 2021; 11(1):292-303. PubMed ID: 33391475
[TBL] [Abstract][Full Text] [Related]
26. Poor Applicability of Currently Available Prognostic Scoring Systems for Prediction of Outcome in
Naumann N; Rudelius M; Lübke J; Christen D; Bresser J; Sotlar K; Metzgeroth G; Fabarius A; Hofmann WK; Panse J; Horny HP; Cross NCP; Reiter A; Schwaab J
Cancers (Basel); 2024 Jan; 16(3):. PubMed ID: 38339343
[TBL] [Abstract][Full Text] [Related]
27. Antibody-Based and Cell Therapies for Advanced Mastocytosis: Established and Novel Concepts.
Valent P; Akin C; Arock M; Gleixner KV; Greinix H; Hermine O; Horny HP; Ivanov D; Orfao A; Rabitsch W; Reiter A; Schulenburg A; Sotlar K; Sperr WR; Ustun C
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894806
[TBL] [Abstract][Full Text] [Related]
28. Impact of centralized evaluation of bone marrow histology in systemic mastocytosis.
Jawhar M; Schwaab J; Horny HP; Sotlar K; Naumann N; Fabarius A; Valent P; Cross NC; Hofmann WK; Metzgeroth G; Reiter A
Eur J Clin Invest; 2016 May; 46(5):392-7. PubMed ID: 26914980
[TBL] [Abstract][Full Text] [Related]
29. Acute mast cell leukemia without KIT D816V mutation and lack of CD2 and CD25-a case report of rare entity.
Zaremba-Pataj E; Patkowska E; Krzywdzińska A; Szumera-Ciećkiewicz A; Chlebowska-Tuz J
J Hematop; 2023 Mar; 16(1):39-47. PubMed ID: 38175371
[TBL] [Abstract][Full Text] [Related]
30. Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis: A retrospective analysis of the DRST and GREM registries.
Lübke J; Christen D; Schwaab J; Kaiser A; Naumann N; Shoumariyeh K; Jentzsch M; Sockel K; Schaffrath J; Ayuk FA; Stelljes M; Hilgendorf I; Sala E; Kaivers J; Schönland S; Wittke C; Hertenstein B; Radsak M; Kaiser U; Brückl V; Kröger N; Brümmendorf TH; Hofmann WK; Klein S; Jost E; Reiter A; Panse J
Leukemia; 2024 Apr; 38(4):810-821. PubMed ID: 38448757
[TBL] [Abstract][Full Text] [Related]
31. Mast cell leukemia with novel BRAF variant and concomitant atypical KIT variant.
Chen T; Malysz J; Washburn E; Songdej N; Zhang Y; Bayerl M
Cancer Genet; 2022 Aug; 266-267():33-36. PubMed ID: 35717863
[TBL] [Abstract][Full Text] [Related]
32. Identification of MCL1 as a novel target in neoplastic mast cells in systemic mastocytosis: inhibition of mast cell survival by MCL1 antisense oligonucleotides and synergism with PKC412.
Aichberger KJ; Mayerhofer M; Gleixner KV; Krauth MT; Gruze A; Pickl WF; Wacheck V; Selzer E; Müllauer L; Agis H; Sillaber C; Valent P
Blood; 2007 Apr; 109(7):3031-41. PubMed ID: 17110460
[TBL] [Abstract][Full Text] [Related]
33. Systemic Mastocytosis: Advances in Diagnosis and Current Management.
Pullarkat ST; Wu W; Pullarkat V
Cancer Treat Res; 2021; 181():167-178. PubMed ID: 34626361
[TBL] [Abstract][Full Text] [Related]
34. Diagnosis and management of mastocytosis: an emerging challenge in applied hematology.
Valent P
Hematology Am Soc Hematol Educ Program; 2015; 2015():98-105. PubMed ID: 26637707
[TBL] [Abstract][Full Text] [Related]
35. Standards of Pathology in the Diagnosis of Systemic Mastocytosis: Recommendations of the EU-US Cooperative Group.
Sotlar K; George TI; Kluin P; Reiter A; Schwaab J; Panse J; Brockow K; Hartmann K; Sperr WR; Kristensen T; Nedoszytko B; Carter M; Bonadonna P; Lyons JJ; Kluin-Nelemans HC; Hermine O; Akin C; Broesby-Olsen S; Hoermann G; Triggiani M; Butterfield JH; Jawhar M; Gotlib J; Metcalfe DD; Orfao A; Arock M; Valent P; Horny HP
J Allergy Clin Immunol Pract; 2022 Aug; 10(8):1986-1998.e2. PubMed ID: 35724949
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial.
DeAngelo DJ; George TI; Linder A; Langford C; Perkins C; Ma J; Westervelt P; Merker JD; Berube C; Coutre S; Liedtke M; Medeiros B; Sternberg D; Dutreix C; Ruffie PA; Corless C; Graubert TJ; Gotlib J
Leukemia; 2018 Feb; 32(2):470-478. PubMed ID: 28744009
[TBL] [Abstract][Full Text] [Related]
37. From the observation of atypical cells on blood smear to the diagnosis of mast cell leukemia: a case report in a 79 year old woman consulting for anemia.
Decker J; Meyer S; Latger-Cannard V; Visanica S; Loppinet E; Lesesve JF; Bénet B
Ann Biol Clin (Paris); 2017 Dec; 75(6):689-694. PubMed ID: 29043985
[TBL] [Abstract][Full Text] [Related]
38. Diagnostic criteria and classification of mastocytosis: a consensus proposal.
Valent P; Horny HP; Escribano L; Longley BJ; Li CY; Schwartz LB; Marone G; Nuñez R; Akin C; Sotlar K; Sperr WR; Wolff K; Brunning RD; Parwaresch RM; Austen KF; Lennert K; Metcalfe DD; Vardiman JW; Bennett JM
Leuk Res; 2001 Jul; 25(7):603-25. PubMed ID: 11377686
[TBL] [Abstract][Full Text] [Related]
39. A new humanized in vivo model of KIT D816V+ advanced systemic mastocytosis monitored using a secreted luciferase.
Bibi S; Zhang Y; Hugonin C; Mangean MD; He L; Wedeh G; Launay JM; Van Rijn S; Würdinger T; Louache F; Arock M
Oncotarget; 2016 Dec; 7(50):82985-83000. PubMed ID: 27783996
[TBL] [Abstract][Full Text] [Related]
40. Kit Mutations: New Insights and Diagnostic Value.
Falchi L; Verstovsek S
Immunol Allergy Clin North Am; 2018 Aug; 38(3):411-428. PubMed ID: 30007460
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
